Disease-Vaccine-Landing-Page/side-panel/vaccine

In September 2023, the FDA issued an EUA for an updated Moderna COVID-19 mRNA vaccine for use in children aged 6 months through 11 years of age to target the...

In October 2023, the FDA issued an EUA to Novavax for its adjuvanted COVID-19 vaccine containing spike protein from the Omicron XBB.1.5 variant of SARS-CoV-2. The FDA initially issued an EUA...

On September 11, 2023, the FDA approved an updated mRNA COVID-19 vaccine developed and manufactured by Moderna for use in persons 12 years and older to target the Omicron variant...

In September 2023, the FDA granted an EUA for an updated Pfizer-BioNTech mRNA COVID-19 vaccine for use in children aged 6 months through 4 years of age to target the...

In September 2023, the FDA issued an EUA for an updated Pfizer-BioNTech COVID-19 mRNA vaccine for use in children aged five through 11 years of age to target the Omicron...

In September 2023, the FDA approved an updated mRNA COVID-19 vaccine developed and manufactured by Pfizer-BioNTech for use in persons 12 years and older to target the Omicron variant XBB.1.5. Comirnaty...

According to the FDA, vaccine makers may submit an application to have their products approved under an Emergency Use Authorization (EUA). Under EUA authority, the FDA Commissioner may permit “unapproved medical...